Morgan Stanley said in a report that Alibaba Health Information Technology (00241.HK) is expected to record a net loss of no more than 320 million yuan in the six months ending September this year (the first half of fiscal year 2022). Compared with the bank's original expected loss of 12 million yuan, the loss is mainly due to the group's increased allocation of resources to invest in a series of innovative businesses such as medical deer APP and health insurance. The company is also engaged in pharmaceutical supply chain capabilities such as pharmaceutical warehousing and logistics, as well as pharmaceutical self-business and continuous investment in technology research and development. The bank expects Alibaba Health Information Technology to announce results for the first half of fiscal year 2022 in late November, with sales revenue estimated to grow by about 30%. With more promotional activities in the second half of fiscal year, revenue growth is expected to be higher in the second half of fiscal year 2022, but similar losses or losses are expected to expand at the same time.